Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Leukostasis syndrome
ADR ID BADD_A06759
ADR Hierarchy
22      Respiratory, thoracic and mediastinal disorders
22.01      Lower respiratory tract disorders (excl obstruction and infection)
22.01.03      Pulmonary oedemas
22.01.03.008      Leukostasis syndrome
17      Nervous system disorders
17.02      Neurological disorders NEC
17.02.10      Nervous system disorders NEC
17.02.10.018      Leukostasis syndrome
01      Blood and lymphatic system disorders
01.02      White blood cell disorders
01.02.01      Leukocytoses NEC
01.02.01.011      Leukostasis syndrome
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.32      Neoplasm related morbidities
16.32.03      Oncologic complications and emergencies
16.32.03.018      Leukostasis syndrome
Description Abnormal intravascular leukocyte aggregation and clumping often seen in leukemia patients. The brain and lungs are the two most commonly affected organs. This acute syndrome requires aggressive cytoreductive modalities including chemotherapy and/or leukophoresis. It is differentiated from LEUKEMIC INFILTRATION which is a neoplastic process where leukemic cells invade organs. [MeSH]
MedDRA Code 10074608
MeSH ID D018921; D018921; D018921
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Leukostasis | Pulmonary leukostasis | Leukostasis syndrome | Hyperleukocytic syndrome | Leukostases | Leukostasis Syndrome | Leukostasis Syndromes | Syndrome, Leukostasis | Syndromes, Leukostasis
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00194Azacitidine0.000112%
BADD_D01110Hydroxyurea0.000112%
BADD_D01119Ibrutinib0.000336%
BADD_D01789Plerixafor octahydrochloride--
BADD_D01978Ruxolitinib0.000137%
BADD_D02482Acalabrutinib0.000168%
The 1th Page    1    Total 1 Pages